Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
Homologe en heterologe COVID-19-boostervaccinaties veilig en immunogeen
mrt 2022 | Vaccinatie, Virale infecties